Analyzing Black Titan (BTTC) & Its Peers

Black Titan (NASDAQ:BTTCGet Free Report) is one of 48 publicly-traded companies in the “Services – Computer Programming And Data Processing” industry, but how does it contrast to its rivals? We will compare Black Titan to similar businesses based on the strength of its profitability, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Black Titan and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Black Titan 1 0 0 0 1.00
Black Titan Competitors 97 199 217 14 2.28

As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 130.59%. Given Black Titan’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Black Titan has less favorable growth aspects than its rivals.

Profitability

This table compares Black Titan and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Black Titan N/A -108.60% -95.64%
Black Titan Competitors -37.96% -997.94% -64.24%

Earnings & Valuation

This table compares Black Titan and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Black Titan $2.68 million -$4.71 million -0.58
Black Titan Competitors $233.98 million -$56.06 million -10.78

Black Titan’s rivals have higher revenue, but lower earnings than Black Titan. Black Titan is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

57.9% of shares of all “Services – Computer Programming And Data Processing” companies are held by institutional investors. 53.7% of Black Titan shares are held by company insiders. Comparatively, 20.6% of shares of all “Services – Computer Programming And Data Processing” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Black Titan has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s rivals have a beta of 0.54, indicating that their average share price is 46% less volatile than the S&P 500.

Summary

Black Titan rivals beat Black Titan on 7 of the 13 factors compared.

About Black Titan

(Get Free Report)

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.

Receive News & Ratings for Black Titan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Titan and related companies with MarketBeat.com's FREE daily email newsletter.